Epizyme Gross Margin 2012-2022 | EPZM
Current and historical gross margin for Epizyme (EPZM) over the last 10 years. The current gross profit margin for Epizyme as of March 31, 2022 is %.
| Epizyme Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2022-03-31 |
$0.04B |
$0.03B |
71.79% |
| 2021-12-31 |
$0.04B |
$0.03B |
71.05% |
| 2021-09-30 |
$0.03B |
$0.03B |
76.47% |
| 2021-06-30 |
$0.03B |
$0.03B |
75.76% |
| 2021-03-31 |
$0.02B |
$0.02B |
68.18% |
| 2020-12-31 |
$0.02B |
$0.01B |
73.33% |
| 2020-09-30 |
$0.01B |
$0.01B |
72.73% |
| 2020-06-30 |
$0.01B |
$0.01B |
92.31% |
| 2020-03-31 |
$0.02B |
$0.02B |
100.00% |
| 2019-12-31 |
$0.02B |
$0.02B |
100.00% |
| 2019-09-30 |
$0.03B |
$0.03B |
100.00% |
| 2019-03-31 |
$0.03B |
$0.03B |
100.00% |
| 2017-06-30 |
$0.02B |
$0.02B |
100.00% |
| 2016-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2016-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2016-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2016-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2015-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2015-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2015-06-30 |
$0.02B |
$0.02B |
100.00% |
| 2015-03-31 |
$0.03B |
$0.03B |
100.00% |
| 2014-12-31 |
$0.04B |
$0.04B |
100.00% |
| 2014-09-30 |
$0.07B |
$0.07B |
100.00% |
| 2014-06-30 |
$0.07B |
$0.07B |
100.00% |
| 2014-03-31 |
$0.07B |
$0.07B |
100.00% |
| 2013-12-31 |
$0.07B |
$0.07B |
100.00% |
| 2013-06-30 |
$0.04B |
$0.04B |
100.00% |
| 2013-03-31 |
$0.04B |
$0.04B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.075B |
$0.037B |
|
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
|
